Trademark Overview
On Friday, January 31, 2025, a trademark application was filed for QINTRALI with the United States Patent and Trademark Office. The USPTO has given the QINTRALI trademark a serial number of 99024609. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Tuesday, July 15, 2025. This trademark is owned by Merck Sharp & Dohme B.V.. The QINTRALI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment and prevention of bone, cardiovascular, central nervous system, dermatological, endocrine, hematological, hepatological, immunological, gastrointestinal, genitourinary, gynecological, metabolic, musculoskeletal, nephrological, neurological, oncological, ophthalmic, psychiatric, pulmonary, renal, respiratory, and urological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of autoimmune diseases, asthma, cancer and tumors, chronic cough, diabetes, hypertension, insomnia, intestinal infections, skin disorders, and urinary incontinence; Inhalers filled with pharmaceutical preparations for the treatment of cardiovascular diseases and disorders; Antibacterial pharmaceuticals; Antibiotics; Antifungal preparations; Anti-infectives; Anti-inflammatories; Antiparasitics; Antivirals; Human vaccine preparations
